Dr. Grace L. Federman, MD

Dr. Federman practices at Advanced Dermcare in Danbury, Connecticut.

Dr. Federman's NPI, 1033160924, was assigned on May 15, 2006. Dr. Federman graduated from New York University School of Medicine in 1986. Dr. Federman holds Connecticut license 033025.

Dr. Federman's primary practice is Advanced Dermcare, at 25 Tamarack Ave Advanced Derm Care Pc, Danbury, CT 06811-4829. The practice phone is (203) 797-8990.

Dr. Federman's primary practice is Advanced Dermcare in Danbury, Connecticut. Dr. Federman is also affiliated with Northwell Danbury Hospital. The medical group on file is Advanced DermCare.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Federman practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Federman's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Federman is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Federman's licenses on file in 3 states: Connecticut, New York and Florida.

Dmand AI lists acne, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, itchy rashes, joint cyst, psoriasis and rash among the conditions Dr. Federman treats.

CMS data shows 3,561 Medicare services from Dr. Federman across 17 procedure codes in 2024, for 1,040 Medicare patients. Medicare paid $177,891 for them. Every service was in an office.

CMS counts 1,040 Medicare patients who saw Dr. Federman in 2024. The largest group is 75 to 84, with 466 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 6% are also on Medicaid. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Federman's median patient age at 74, with 70% women.

In 2024, Dr. Federman wrote 1,375 Medicare Part D claims for 569 patients. 93% of them were for generic drugs. CMS names the drug for 1,221 of them, across 26 drugs with 11 or more claims each, at $79,655 in total drug cost. In 2023, CMS named 1,046 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Federman for performance year 2024, reported as part of a group. Dr. Federman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 806 procedures of removal of skin lesions by Dr. Federman, more than 91% of the clinicians it reports for that procedure.

Removal of skin cancer: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Federman. Dr. Federman's most frequent co-author is Robert S. Kirsner, MD.

CMS Open Payments shows 788 general payments to Dr. Federman from 44 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Abbvie Inc. paid the most, $2,465.

Dmand AI lists 2 awards for Dr. Federman.

Dr. Federman graduated from New York University School of Medicine in 1986. Dr. Federman is a member of AAD.

Dr. Federman is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.